GRDN
Guardian Pharmacy Services, Inc.
GRDN has a slight edge over OSCR overall, supported by lower modeled downside and stronger modeled upside.
OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
GRDN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
GRDN's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
GRDN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 34x | $49.38 | — |
| Current | 42x | $49.38 | — |
| Cheap | 44x | $51.74 | +4.8% |
| Fair | 48x | $56.09 | +14% |
| Expensive | 51x | $59.75 | +21% |
Historical ranges are pointers, not guarantees.
GRDN's PE is in its cheap range at 42x. If earnings grow as analysts expect, today's price would be 34x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over GRDN in the historical PE scenario, which offers more potential upside but is not a forecast.
GRDN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for GRDN, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
GRDN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.47 | +25% |
| Q3 2026 | $1.17 | +83% |
| Q2 2026 | $1.03 | +$2.54 |
| Q1 2026 | $0.83 | +$2.31 |
| Q4 2025 | $0.77 | +$2.54 |
| Q3 2025 | $0.64 | +$2.23 |
| Q2 2025 | -$1.51 | -786% |
| Q1 2025 | -$1.48 | -470% |
| Q4 2024 | -$1.77 | -411% |
GRDN has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
GRDN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $371.1M | -1.7% |
| Q2 2026 | $351.8M | +2.2% |
| Q1 2026 | $336.6M | +2.2% |
| Q4 2025 | $397.6M | +17% |
| Q3 2025 | $377.4M | +20% |
| Q2 2025 | $344.3M | +15% |
| Q1 2025 | $329.3M | +20% |
| Q4 2024 | $338.6M | +20% |
GRDN's revenue is growing: $371M last quarter, down 1.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.8% | +2.3 points |
| Q2 2026 | 5.9% | +2.2 points |
| Q1 2026 | 5.3% | +1.3 points |
| Q4 2025 | 9.2% | +4.2 points |
| Q3 2025 | 4.5% | +38 points |
| Q2 2025 | 3.6% | -2 points |
| Q1 2025 | 4% | +1.1 points |
| Q4 2024 | 5% | -0.6 points |
GRDN has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over GRDN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
GRDN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $43.4M | +89% |
| Q2 2026 | $25.4M | +63% |
| Q1 2026 | $1M | -91% |
| Q4 2025 | $30.4M | +70% |
| Q3 2025 | $23M | +$30.3M |
| Q2 2025 | $15.6M | -40% |
| Q1 2025 | $11.7M | +137% |
| Q4 2024 | $17.8M | +51% |
GRDN generated $100M in free cash flow over the past year, up 47% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
GRDN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +80K shares |
| 1 year | +0.8% | +484K shares |
| 3 years | +5% | +3.1M shares |
| 5 years | +5% | +3.1M shares |
| Available history | +5% | +3.1M shares |
GRDN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | $30.3M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $29M |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
GRDN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -0.5x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2024 | 1.4x | Healthy |
| Q1 2024 | -0.0x | Net Cash |
| Q4 2023 | 1.2x | Healthy |
GRDN has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over GRDN on leverage, with a lower net debt burden relative to earnings.
GRDN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 67.4 | Neutral |
| Stochastic | 60.9 | Neutral |
GRDN's weekly RSI is 67 (neutral) and its Stochastic is 61 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
GRDN PE vs Healthcare Sector
| Metric | GRDN | Sector median | Relative |
|---|---|---|---|
| PE | 42x | 26x | 63% above |
| PE % | 8 | 59 | 51 pts below |
GRDN is trading at 42x earnings, a 63% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over GRDN on valuation relative to its sector.
GRDN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $42.0 | 17% above |
| 20 week MA | $41.3 | 20% above |
| 50 week MA | $37.5 | 32% above |
| 100 week MA | $30.3 | 63% above |
OSCR has stronger trend alignment. GRDN is above 4 of 4 weekly averages versus OSCR above 5 of 5.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
GRDN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $17.8 | $21.2 | +19% |
| 2025 | $21.2 | $30.7 | +45% |
| 2026 YTD | $30.7 | $49.4 | +61% |
GRDN has finished every year since 2024 higher, and it's up 61% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over GRDN on returns for 2026, with the stronger performance.